Join Netsmart and Denver Recovery Group to learn how one organization as operationalized a low-barrier model of care through initiatives such as Treatment on Demand.
Join Netsmart and Denver Recovery Group to learn how one organization as operationalized a low-barrier model of care through initiatives such as Treatment on Demand.
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
New randomized controlled trial data presented at ASAM 2026 highlighted the benefits of integrating Written Exposure Therapy (WET) into residential substance use disorder (SUD) treatment.
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
At the 2026 New York Society of Addiction Medicine (NYSAM) Annual Conference in New York, clinicians and policymakers focused on integrating evolving policy with patient-centered addiction care.
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
Evguenia Makovkina, MD, discusses key findings from her pilot study examining psychiatrists’ baseline knowledge, attitudes, and prescribing practices related to medications for opioid use disorder (mOUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
A review published in the Journal of the Endocrine Society highlights the emerging potential of GLP-1 receptor agonists (GLP-1RAs) as pharmacotherapies for alcohol and substance use disorders (ASUDs).
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Second-generation heart rate variability biofeedback (HRVB) reduced negative affect, craving, and substance use in individuals in early recovery from severe substance use disorder (SUD), according to phase 2 trial results.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
HHS announced up to $4.9 million over 5 years through ARPA-H to support ibogaine development for PTSD and other serious mental illnesses, including preparations for future US trials and domestic manufacturing.
HHS announced up to $4.9 million over 5 years through ARPA-H to support ibogaine development for PTSD and other serious mental illnesses, including preparations for future US trials and domestic manufacturing.
A single 100m dose of DT120 (lysergide), a classic serotonergic psychedelic that acts as a partial agonist at serotonin-2A receptors, significantly reduced major depressive disorder (MDD) symptoms compared with placebo in the phase 3 Emerge...
A single 100m dose of DT120 (lysergide), a classic serotonergic psychedelic that acts as a partial agonist at serotonin-2A receptors, significantly reduced major depressive disorder (MDD) symptoms compared with placebo in the phase 3 Emerge...
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Compass Pathways has completed submission of a New Drug Application for COMP360, an investigational synthetic psilocybin formulation for adults with treatment-resistant depression.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
Psilocybin administration was associated with reductions in markers of systemic inflammation and mitochondrial stress among people with PD and mood dysfunction, according to a research letter published in JAMA Psychiatry.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
Melanie Barrett, MD, discusses how mental health care providers can address gaps in postpartum depression screening, diagnosis, and treatment in clinical practice.
Melanie Barrett, MD, discusses how mental health care providers can address gaps in postpartum depression screening, diagnosis, and treatment in clinical practice.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
